SCHEMBL4954846

SCHEMBL4954846

Oc1ccccc1-c1conn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.43
NR1I2 O75469 3/20 0.42
SMARCA2 P51531 3/20 0.42
SMARCA4 P51532 3/20 0.42
PBRM1 Q86U86 3/20 0.42
BRD4 O60885 1/20 0.42
HPGD P15428 6/20 0.40
HSD17B10 Q99714 3/20 0.40
ALDH1A1 P00352 2/20 0.40
BCL2L1 Q07817 1/20 0.40
SMN1; SMN2 Q16637 9/20 0.39
MAPT P10636 6/20 0.39
CYP1A2 P05177 4/20 0.39
CYP2C9 P11712 4/20 0.39
CYP2C19 P33261 4/20 0.39
CYP3A4 P08684 2/20 0.39
GAA P10253 1/20 0.39
AGTR1 P30556 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CASP3 P42574 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27651172 0.98 IDO1 (0.42) IDO1NR1I2SMARCA2SMARCA4PBRM1
SCHEMBL28691784 0.92 HPGD (0.38) IDO1NR1I2SMARCA2SMARCA4PBRM1
SCHEMBL6135309 0.76 GPR55 (0.39) NR1I2SMARCA2SMARCA4PBRM1BRD4
SCHEMBL6348373 0.76 CASP3 (0.35) CASP3SENP8SENP7SENP6
SCHEMBL7736978 0.76
SCHEMBL5152908 0.76 ALDH1A1 (0.52) IDO1HPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL2679546 0.76 RAB9A (0.48) IDO1HPGDHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL7903481 0.76 ENPP2 (0.33)
SCHEMBL2200428 0.74 GPR55 (0.38) NR1I2SMARCA2SMARCA4PBRM1BRD4
SCHEMBL3062578 0.73 ENPP3 (0.44) HPGDHSD17B10ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528892-B2 Alkylation of transition metal coordination catalyst complexes EXXONMOBIL CHEMICAL PATENTS INC. (US) 2026-01-20 US claimed
US-20230141606-A1 Alkylation of Transition Metal Coordination Catalyst Complexes EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-05-11 US claimed
WO-2021194831-A1 ALKYLATION OF TRANSITION METAL COORDINATION CATALYST COMPLEXES EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-09-30 WO claimed
CN-113948650-B Light emitting device and electronic apparatus including the same 三星显示有限公司 2026-05-22 CN disclosed
US-12635330-B2 Light-emitting device and electronic apparatus including the same SAMSUNG DISPLAY CO., LTD. (KR) 2026-05-19 US disclosed
US-12635404-B2 Organometallic compound and light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2026-05-19 US disclosed
US-12630576-B2 Light-emitting device including organometallic compound, electronic apparatus including the light-emitting device, and the organometallic compound SAMSUNG DISPLAY CO., LTD. (KR) 2026-05-19 US disclosed
US-12635410-B2 Light-emitting device and electronic apparatus including the same SAMSUNG DISPLAY CO., LTD. (KR) 2026-05-19 US disclosed
US-12630732-B2 Scattering particle, ink composition including the same, and display apparatus including quantum dot layer prepared by using the ink composition SAMSUNG DISPLAY CO., LTD. (KR) 2026-05-19 US disclosed
CN-122037923-A Quantum dot, optical member and electronic device comprising the same, and method for preparing the quantum dot 三星显示有限公司 2026-05-15 CN disclosed
US-20260132332-A1 QUANTUM DOT, OPTICAL MEMBER AND ELECTRONIC APPARATUS INCLUDING THE QUANTUM DOT, AND METHOD FOR PREPARING QUANTUM DOT SAMSUNG DISPLAY CO LTD (KR) 2026-05-14 US disclosed
EP-3219714-A1 COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME Samsung Display Co., Ltd. (KR) 2017-09-20 EP disclosed
US-7402583-B2 Substituted quinolines as antitumor agents ASTRZENCA AB (SE) 2008-07-22 US disclosed
US-20070021407-A1 Substituted quinolines as antitumor agents ASTRAZENECA 2007-01-25 US disclosed
US-7067532-B2 Substituted quinolines as antitumor agents ASTRAZENECA (SE) 2006-06-27 US disclosed
US-20040029898-A1 Substituted quinolines as antitumor agents ASTRAZENECA AB (SE) 2004-02-12 US disclosed
EP-1337524-A1 SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2003-08-27 EP disclosed
WO-2002044166-A1 SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2002-06-06 WO disclosed
US-5643929-A TREATMENT OF PICORNAVIRAL OR RHINOVIRUS AND CHEMICAL INTERMEDIATES SANOFI WINTHROP, INC. (US) 1997-07-01 US disclosed
US-5464848-A 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents STERLING WINTHROP INC. (US) 1995-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528892-B2 Alkylation of transition metal coordination catalyst complexes LEF1, TAF1, FLI1 IDO1 1515/4885NR1I2 3252/4885SMARCA2 342/4885
US-20070021407-A1 Substituted quinolines as antitumor agents NR1H3, NR1H2, NR0B1 IDO1 1856/4885NR1I2 21/4885SMARCA2 2674/4885
US-12630732-B2 Scattering particle, ink composition including the same, and display apparatus including quantum dot layer prepared by using the ink composition IK, INCENP, TYR IDO1 290/4885NR1I2 4368/4885SMARCA2 1481/4885
US-20040029898-A1 Substituted quinolines as antitumor agents NQO2, NQO1, TP53 IDO1 122/4885NR1I2 1210/4885SMARCA2 3381/4885
US-12635330-B2 Light-emitting device and electronic apparatus including the same L1CAM, EEA1, PAX3 IDO1 759/4885NR1I2 3443/4885SMARCA2 2549/4885
US-20230141606-A1 Alkylation of Transition Metal Coordination Catalyst Complexes AS3MT, AP1M1, AP3M1 IDO1 3115/4885NR1I2 4106/4885SMARCA2 582/4885
US-12635410-B2 Light-emitting device and electronic apparatus including the same CYBA, RPL21, CYC1 IDO1 1892/4885NR1I2 672/4885SMARCA2 3703/4885
US-12630576-B2 Light-emitting device including organometallic compound, electronic apparatus including the light-emitting device, and the organometallic compound ZC3HAV1L, SOD1, GPS1 IDO1 1462/4885NR1I2 1014/4885SMARCA2 4510/4885
US-20260132332-A1 QUANTUM DOT, OPTICAL MEMBER AND ELECTRONIC APPARATUS INCLUDING THE QUANTUM DOT, AND METHOD FOR PREPARING QUANTUM DOT SOD3, SOD1, YBX3 IDO1 2524/4885NR1I2 3277/4885SMARCA2 2190/4885
US-12635404-B2 Organometallic compound and light-emitting device including the same SOD1, GPS1, SLC39A11 IDO1 482/4885NR1I2 889/4885SMARCA2 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.